Supplementary Table 2.
Characteristics and Outcomes of Patients With IBD Who Received Corticosteroid Therapy 3 Months Preceding the Diagnosis of COVID-19 Compared to Patients With IBD Who Did Not
| Demographics | Before propensity score matching |
After propensity score matching |
||||
|---|---|---|---|---|---|---|
| Steroids | Nonsteroids | P value | Steroids | Nonsteroids | P value | |
| Number of patients | 71 | 161 | 62 | 62 | ||
| Age, y, mean ± SD | 51.3 ± 14.1 | 51.1 ± 19.6 | .93 | 50.2 ± 14.1 | 46.9 ± 20.7 | .31 |
| Female, n (%) | 44 (61.97) | 10,937 (55.30) | .77 | 40 (64.51) | 42 (67.74) | .71 |
| Male, n (%) | 27 (38.02) | 58 (36.02) | .77 | 22 (35.48) | 20 (32.25) | .71 |
| Race, n (%) | ||||||
| White | 51 (71.83) | 126 (78.26) | .28 | 45 (72.58) | 46 (74.19) | .83 |
| Black or African American | 10a (14.08) | 21 (13.04) | — | 10a (16.12) | 10a (16.12) | — |
| Unknown race | 11 (15.49) | 12 (7.45) | .05 | 10a (16.12) | 10a (16.12) | — |
| Body Mass Index (BMI) kg/m2 | 30.7 ± 7.81 | 29 ± 7.2 | .09 | 30.3 ± 8.05 | 29.6 ± 7.58 | .63 |
| Comorbid conditions, n (%) | ||||||
| Essential hypertension | 43 (60.56) | 78 (48.44) | .08 | 34 (54.84) | 31 (50) | .58 |
| Chronic lower respiratory diseases (asthma and COPD) | 42 (59.15) | 49 (30.43) | <.0001 | 34 (54.83) | 36 (58.06) | .71 |
| Diabetes mellitus | 24 (33.80) | 38 (23.60) | .11 | 18 (29.03) | 16 (25.80) | .68 |
| Heart failure | 20 (28.17) | 17 (10.55) | <.0001 | 14 (22.58) | 11 (17.74) | .5 |
| Ischemic heart diseases | 20 (28.17) | 29 (18.01) | .08 | 14 (22.58) | 13 (20.96) | .83 |
| Chronic kidney disease | 19 (26.76) | 20 (12.42) | <.0001 | 12 (19.35) | 10 (16.13) | .63 |
| Outcomes | Before propensity matching |
After propensity matching |
||||
|---|---|---|---|---|---|---|
| Overall risk, n (%) | Risk ratio (95% confidence interval) | P value | Overall risk, n (%) | Risk ratio (95% confidence interval) | P value | |
| Severe COVID-19 | Steroids: 22 (30.98) | 1.60 (1.01–2.57) | 0.04 | Steroids: 18 (29.03) | b | — |
| Nonsteroids: 31 (19.25) | Nonsteroids ≤10a (≤16.13) | |||||
a
Numbers rounded off to 10 to protect HPI.
b
Risk ratio cannot be estimated because of outcomes of ≤10 in the nonsteroid group.